v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue $ 4,136,320 $ 4,617,541
Cost of goods sold 3,742,576 4,492,485
Gross Profit 393,744 125,056
Operating Expenses:    
Selling expenses 980,674 718,016
General and administrative expenses 1,414,145 1,362,246
Research and development expenses 276,134 230,123
Total Operating Expenses 2,670,953 2,310,385
Loss from Operations (2,277,209) (2,185,329)
Other Income (Expense):    
Interest and other income 16,857 68,751
Interest and other expense (209,064) (48,283)
Amortization of debt discount (87,504) (168,030)
Gain (loss) on foreign currency transactions (168,556) 35,516
Gain (loss) on disposal of property and equipment 0 (61,306)
Total Other Expense (448,267) (173,352)
Loss Before Income Taxes (2,725,476) (2,358,681)
Income tax benefit (377) (339)
Net Loss (2,725,099) (2,358,342)
Net Loss attributable to noncontrolling interest (14,987) (6,950)
Net Loss attributable to LiqTech International, Inc. $ (2,710,112) $ (2,351,392)
Loss Per Common Share – Basic and Diluted (in dollars per share) $ (0.28) $ (0.25)
Weighted-Average Common Shares Outstanding – Basic and Diluted (in shares) 9,847,218 9,602,354